Becton, Dickinson and Company (BDX) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
2 Feb, 2026Opening remarks and agenda
Quorum confirmed, shareholders able to vote online or by proxy if not already voted.
Financial performance review
Achieved record revenue of $21.8 billion in FY 2025, with 7.7% adjusted FXN and 2.9% organic growth.
Adjusted gross margin increased by 140 basis points, operating margin up 80 basis points, and adjusted diluted EPS grew 9.6%.
Returned $2.2 billion to shareholders, including $1 billion in share buybacks.
54th consecutive year of dividend increases, maintaining S&P 500 Dividend Aristocrats status.
Board and executive committee updates
Election of director nominees for a one-year term was on the agenda.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Becton, Dickinson and Company
- Hedging, innovation, and new platforms drive growth and resilience amid global challenges.BDX
Barclays 28th Annual Global Healthcare Conference10 Mar 2026 - Q1 FY26 revenue up 1.6% to $5.3B; $4B from Waters deal funds buybacks and debt paydown.BDX
Q1 20269 Feb 2026 - Q3 FY24 saw strong growth, margin gains, and a $4.2B acquisition amid ongoing legal risks.BDX
Q3 20242 Feb 2026 - Strong innovation, margin expansion, and AI-driven growth position the company for continued outperformance.BDX
2024 Wells Fargo Healthcare Conference22 Jan 2026 - Strong FY24 results and FY25 outlook with margin expansion, innovation, and resilient growth.BDX
Q4 202416 Jan 2026 - 2025 outlook features prudent growth targets, margin expansion, and strong product innovation.BDX
7th Annual Evercore ISI HealthCONx Conference12 Jan 2026 - Q1 revenue up 9.8% to $5.2B, EPS up 28%, and Biosciences separation planned for FY26.BDX
Q1 20258 Jan 2026 - Separation of Biosciences division and MedTech focus set to accelerate growth and innovation.BDX
Citi’s 2025 Medtech and Life Sciences Access Day7 Jan 2026 - Q2 revenue up 4.5% and adjusted EPS up 5.7%, with FY2025 EPS guidance raised despite headwinds.BDX
Q2 202525 Dec 2025